Aslan Pharmaceuticals Ltd ADR (ASLN) | |||
---|---|---|---|
0.631 -0.004 (-0.63%) | 03-27 16:00 | ||
Open: | 0.629 | Pre. Close: | 0.635 |
High: | 0.65 | Low: | 0.6098 |
Volume: | 215,585 | Market Cap: | 11(M) |
Stock Technical Analysis | |
---|---|
Overall: | |
Target: | Six months: 1.69 One year: 2.44 |
Support: | Support1: 0.40 Support2: 0.33 |
Resistance: | Resistance1: 1.44 Resistance2: 2.09 |
Pivot: | 0.74 |
Moving Averages: | MA(5): 0.65 MA(20): 0.73 MA(100): 0.67 MA(250): 1.95 |
MACD: | MACD(12,26): 0.01 Signal(12,26,9): 0.03 |
%K %D: | %K(14,3): 5.58 %D(3): 6.34 |
RSI: | RSI(14): 48.40 |
52-Week: | High: 4.69 Low: 0.392 Change(%): -76.1 |
Average Vol(K): | 3-Month: 1026 10-Days: 878 |
Prices Prediction (Update @5:00pm) | ||
---|---|---|
If tomorrow: | Open lower | Open higher |
High: | 0.651 - 0.655 | 0.655 - 0.659 |
Low: | 0.6 - 0.604 | 0.604 - 0.608 |
Close: | 0.622 - 0.629 | 0.629 - 0.637 |
Price, MAs and Bollinger Bands |
---|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ASLN ] has closed above bottom band by 38.8%. Bollinger Bands are 112.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue. |
Company profile |
---|
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore. |
Stock chart |
---|
Financial Analysis | |
---|---|
Price to Book Value: | Underperform |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
Price to Earnings: | Underperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
Discounted cash flow: | Outperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
Return on Assets: | Underperform |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
Return on Equity: | Outperform |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
Debt to Equity: | Underperform |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Stock Basics & Statistics | |
---|---|
Exchange: NASDAQ Global Market | |
Sector: Healthcare | |
Industry: Biotechnology | |
Shares Out. (M) | 17.60 |
Shares Float (M) | 370.17 |
% Held by Insiders | 0.05 |
% Held by Institutions | 14.90 |
Shares Short (K) | 19 |
Shares Short Prior Month (K) | 59 |
Stock Financials | |
---|---|
EPS | -3.000 |
Book Value (p.s.) | -0.050 |
Profit Margin | |
Operating Margin | -369.02 |
Return on Assets (ttm) | -47.2 |
Return on Equity (ttm) | -426.6 |
Qtrly Rev. Growth | |
Gross Profit (p.s.) | |
Sales Per Share | 0.682 |
EBITDA (p.s.) | -2.515 |
Qtrly Earnings Growth | |
Operating Cash Flow (M) | |
Levered Free Cash Flow (M) |
Stock Valuation | |
---|---|
PE Ratio | -0.21 |
PEG Ratio | |
Price to Book value | -12.62 |
Price to Sales | 0.93 |
Price to Cash Flow |
Stock Dividends | |
---|---|
Dividend | |
Dividend Yield | |
Dividend Growth |